Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study
{{output}}
Background: ESK-001, a novel allosteric, highly selective oral TYK2 inhibitor in development for treatment of immune-mediated disorders, was well-tolerated, and achieved high levels of target inhibition in Phase 1 studies with he... ...
